House appropriators’ changes in their comments on the US Food and Drug Administration’s work on expanding access to the opioid overdose remedy naloxone miss the point about making it available nonprescription as the agency has emphasized.
The Appropriation Committee’s report published with legislation for the FDA’s fiscal year 2022 funding along with budgets for the Department of Agriculture and related agencies, repeats statements members made for the FDA’s FY2021 budget concerning a proposed rule to facilitate more OTC switches; weight-based dosing instructions for children ages six months to 2 years to
The